Abstract

The discovery of the third histamine receptor and the design of highly selective and potent ligands have not only clarified some aspects of histaminergic neurotransmission in brain: they have also provided us with useful experimental tools to modify this neurotransmission and, therefore, to establish more precisely its roles. Furthermore, in analogy with agents interacting with the two other histamine receptor subtypes, it can be safely anticipated that some of these compounds will constitute novel drugs for the therapeutic management of cerebral and peripheral disorders in humans.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call